{"count": 6, "results": [{"_id": "11485133", "pmid": 11485133, "title": "Fatal fetal outcome with the combined use of valsartan and atenolol.", "journal": "Ann Pharmacother", "authors": ["Briggs GG", "Nageotte MP"], "date": "2001-07-01T00:00:00Z", "doi": "10.1345/aph.1A013", "meta_date_publication": "2001 Jul-Aug", "meta_volume": "35", "meta_issue": "7-8", "meta_pages": "859-61", "score": 50062.15, "text_hl": "This @DISEASE_Drug_Related_Side_Effects_and_Adverse_Reactions @DISEASE_MESH:D064420 @@@toxicity@@@ includes reduced perfusion of the fetal kidneys, resulting in @DISEASE_Anuria @DISEASE_MESH:D001002 @@@anuria@@@, @DISEASE_Oligohydramnios @DISEASE_MESH:D016104 @@@oligohydramnios@@@, and subsequent @DISEASE_Lung_agenesis @DISEASE_MESH:C562992 @@@pulmonary hypoplasia@@@. The small @<m>DISEASE_Lung_Diseases</m> @DISEASE_MESH:D008171 @@@hypoplastic lungs@@@ and very small placenta were probably a consequence of @CHEMICAL_Valsartan @CHEMICAL_MESH:D000068756 @@@valsartan@@@ and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ combination therapy. ", "citations": {"NLM": "Briggs GG, Nageotte MP. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother. 2001 Jul-Aug;35(7-8):859-61. PMID: 11485133", "BibTeX": "@article{11485133, title={Fatal fetal outcome with the combined use of valsartan and atenolol.}, author={Briggs GG and Nageotte MP}, journal={Ann Pharmacother}, volume={35}, number={7-8}, pages={859-61}}"}}, {"_id": "8656342", "pmid": 8656342, "title": "Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy.", "journal": "J Pharmacokinet Biopharm", "authors": ["Yamada Y", "Matsuyama K", "Ito K", "Sawada Y", "Iga T"], "date": "1995-10-01T00:00:00Z", "doi": "10.1007/BF02353469", "meta_date_publication": "1995 Oct", "meta_volume": "23", "meta_issue": "5", "meta_pages": "463-78", "score": 50052.113, "text_hl": "This finding indicates that even @GENE_MS4A1 @GENE_931 @@@beta-1@@@ selective drugs must be administered carefully to @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Lung_Diseases</m> @DISEASE_MESH:D008171 @@@pulmonary disease@@@. Furthermore, the relationship between the pharmacologic or @<m>DISEASE_Lung_Diseases</m> @DISEASE_MESH:D008171 @@@pulmonary effects@@@ and phi 1 or phi 2 has been analyzed quantitatively with a ternary complex model and used to develop rational dosage regimens for beta-1 selective beta-blocking agents, such as @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, to obtain the desired pharmacologic effects with minimum adverse @<m>DISEASE_Lung_Diseases</m> @DISEASE_MESH:D008171 @@@pulmonary effects@@@.", "citations": {"NLM": "Yamada Y, Matsuyama K, Ito K, Sawada Y, Iga T. Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy. J Pharmacokinet Biopharm. 1995 Oct;23(5):463-78. PMID: 8656342", "BibTeX": "@article{8656342, title={Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy.}, author={Yamada Y and Matsuyama K and Ito K and Sawada Y and Iga T}, journal={J Pharmacokinet Biopharm}, volume={23}, number={5}, pages={463-78}}"}}, {"_id": "25131055", "pmid": 25131055, "title": "Ischemic preconditioning and atenolol on lung injury after intestinal ischemia and reperfusion in rats.", "journal": "Transplant Proc", "authors": ["Bonservizi WG", "Koike MK", "Saurim R", "Felix GA", "da Silva SM", "Montero EF", "Taha MO"], "date": "2014-07-01T00:00:00Z", "doi": "10.1016/j.transproceed.2014.05.054", "meta_date_publication": "2014 Jul-Aug", "meta_volume": "46", "meta_issue": "6", "meta_pages": "1862-6", "score": 50050.07, "text_hl": "Likewise, the TBARS levels were decreased by both strategies (I-R + SS = 0.63; I-R + IPC = 0.23; I-R + @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@AT@@@ = 0.38; P < .05). Our results showed that @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@AT@@@ and IPC attenuate @<m>DISEASE_Lung_Diseases</m> @DISEASE_MESH:D008171 @@@pulmonary lesions@@@ caused by @DISEASE_Intestinal_Diseases @DISEASE_MESH:D007410 @@@intestinal I and R@@@ process. ", "citations": {"NLM": "Bonservizi WG, Koike MK, Saurim R, Felix GA, da Silva SM, Montero EF, Taha MO. Ischemic preconditioning and atenolol on lung injury after intestinal ischemia and reperfusion in rats. Transplant Proc. 2014 Jul-Aug;46(6):1862-6. PMID: 25131055", "BibTeX": "@article{25131055, title={Ischemic preconditioning and atenolol on lung injury after intestinal ischemia and reperfusion in rats.}, author={Bonservizi WG and Koike MK and Saurim R and Felix GA and da Silva SM and Montero EF and Taha MO}, journal={Transplant Proc}, volume={46}, number={6}, pages={1862-6}}"}}, {"_id": "20082655", "pmid": 20082655, "pmcid": "PMC3922376", "title": "beta-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure", "journal": "J Cell Mol Med", "authors": ["Machackova J", "Sanganalmath SK", "Elimban V", "Dhalla NS"], "date": "2011-03-01T00:00:00Z", "doi": "10.1111/j.1582-4934.2010.01015.x", "meta_date_publication": "2011 Mar", "meta_volume": "15", "meta_issue": "3", "meta_pages": "545-54", "score": 50039.76, "text_hl": "All animals were assessed haemodynamically and echocardiographically and the left ventricle (LV) was processed for the determination of myofibrillar @GENE_DNAH8 @GENE_1769 @@@ATPase@@@ activity, alpha- and beta-myosin heavy chain (@GENE_HLA_C @GENE_3107 @@@MHC@@@) isoforms and gene expression as well as @GENE_TNNI3 @GENE_29248 @@@cardiac troponin I@@@ (@GENE_TNNI3 @GENE_29248 @@@cTnI@@@) phosphorylation. Both @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ and @CHEMICAL_Propranolol @CHEMICAL_MESH:D011433 @@@propranolol@@@ at 20 and 75 mg/kg doses attenuated @DISEASE_Cardiomegaly @DISEASE_MESH:D006332 @@@cardiac hypertrophy@@@ and @<m>DISEASE_Lung_Diseases</m> @DISEASE_MESH:D008171 @@@lung congestion@@@ in addition to increasing LV ejection fraction and LV systolic pressure as well as decreasing heart rate, LV end-diastolic pressure and LV diameters in the @DISEASE_Infarction @DISEASE_MESH:D007238 @@@infarcted@@@ animals. ", "citations": {"NLM": "Machackova J, Sanganalmath SK, Elimban V, Dhalla NS. beta-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure J Cell Mol Med. 2011 Mar;15(3):545-54. PMID: 20082655", "BibTeX": "@article{20082655, title={beta-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure}, author={Machackova J and Sanganalmath SK and Elimban V and Dhalla NS}, journal={J Cell Mol Med}, volume={15}, number={3}, pages={545-54}}"}}, {"_id": "22938894", "pmid": 22938894, "title": "Does selective beta-1 blockade provide bone marrow protection after trauma/hemorrhagic shock?", "journal": "Surgery", "authors": ["Pasupuleti LV", "Cook KM", "Sifri ZC", "Kotamarti S", "Calderon GM", "Alzate WD", "Livingston DH", "Mohr AM"], "date": "2012-09-01T00:00:00Z", "doi": "10.1016/j.surg.2012.06.016", "meta_date_publication": "2012 Sep", "meta_volume": "152", "meta_issue": "3", "meta_pages": "322-30", "score": 50034.695, "text_hl": "METHODS: Male Sprague-Dawley @SPECIES_10116 @@@rats@@@ underwent unilateral @<m>DISEASE_Lung_Diseases</m> @DISEASE_MESH:D008171 @@@lung contusion@@@ (@<m>DISEASE_Lung_Diseases</m> @DISEASE_MESH:D008171 @@@LC@@@) followed by @DISEASE_Shock_Hemorrhagic @DISEASE_MESH:D012771 @@@HS@@@ for 45 minutes. ", "citations": {"NLM": "Pasupuleti LV, Cook KM, Sifri ZC, Kotamarti S, Calderon GM, Alzate WD, Livingston DH, Mohr AM. Does selective beta-1 blockade provide bone marrow protection after trauma/hemorrhagic shock? Surgery. 2012 Sep;152(3):322-30. PMID: 22938894", "BibTeX": "@article{22938894, title={Does selective beta-1 blockade provide bone marrow protection after trauma/hemorrhagic shock?}, author={Pasupuleti LV and Cook KM and Sifri ZC and Kotamarti S and Calderon GM and Alzate WD and Livingston DH and Mohr AM}, journal={Surgery}, volume={152}, number={3}, pages={322-30}}"}}, {"_id": "24662859", "pmid": 24662859, "title": "Do all beta-blockers attenuate the excess hematopoietic progenitor cell mobilization from the bone marrow following trauma/hemorrhagic shock?", "journal": "J Trauma Acute Care Surg", "authors": ["Pasupuleti LV", "Cook KM", "Sifri ZC", "Alzate WD", "Livingston DH", "Mohr AM"], "date": "2014-04-01T00:00:00Z", "doi": "10.1097/TA.0000000000000181", "meta_date_publication": "2014 Apr", "meta_volume": "76", "meta_issue": "4", "meta_pages": "970-5", "score": 50032.586, "text_hl": "This study will determine the role of selective beta-adrenergic receptor blockade in HPC mobilization in a combined model of @<m>DISEASE_Lung_Diseases</m> @DISEASE_MESH:D008171 @@@lung contusion@@@ (@<m>DISEASE_Lung_Diseases</m> @DISEASE_MESH:D008171 @@@LC@@@) and @DISEASE_Shock_Hemorrhagic @DISEASE_MESH:D012771 @@@HS@@@. ", "citations": {"NLM": "Pasupuleti LV, Cook KM, Sifri ZC, Alzate WD, Livingston DH, Mohr AM. Do all beta-blockers attenuate the excess hematopoietic progenitor cell mobilization from the bone marrow following trauma/hemorrhagic shock? J Trauma Acute Care Surg. 2014 Apr;76(4):970-5. PMID: 24662859", "BibTeX": "@article{24662859, title={Do all beta-blockers attenuate the excess hematopoietic progenitor cell mobilization from the bone marrow following trauma/hemorrhagic shock?}, author={Pasupuleti LV and Cook KM and Sifri ZC and Alzate WD and Livingston DH and Mohr AM}, journal={J Trauma Acute Care Surg}, volume={76}, number={4}, pages={970-5}}"}}]}